Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma

R. Lafreniere, S. A. Rosenberg

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences